Status:
TERMINATED
Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome
Lead Sponsor:
Mayo Clinic
Conditions:
Empty Nose Syndrome
Atrophic Rhinitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Empty Nose Syndrome patients suffer from disabling physical symptoms and considerable distress. To date there is no definitive cure for these symptoms. Established treatment modalities include saline ...
Detailed Description
Background: Empty Nose Syndrome (ENS) is the term used to describe the condition resulting from over resection of nasal turbinate. Symptoms include depression, dysosmia, bleeding, discharge, crusting...
Eligibility Criteria
Inclusion
- Any patient aged 18-65 years of age presenting with a known diagnosis of ENS who has no known allergies to Botox.
Exclusion
- Patients younger than 18 years or older than 65 years of age.
- Patients with neuromuscular disorders or neuropathic diseases.
- Patients with infection and or swelling at the site where Botox is to be injected.
- Patients with known hypersensitivity to any ingredient in the drug formulation (botulinum toxin, human albumin)
- Patients who are or plan to become pregnant within the time period in which the study will be conducted.
- Patients who are nursing
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00732680
Start Date
December 1 2008
End Date
November 1 2009
Last Update
April 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55904